Latest Articlesddd
Palm Ebola Clinical Trial Stopped Early as Regeneron Product REGN-EB3 Therapy Shows Superiority to ZMapp in …
Prohost Letter #434 Special Issue The Value of the Biotech Companies With a strong economy and …
Amgen’s Stock Is Up Amgen (AMGN) is speeding towards reaching its true, fair value. In the Q2 …
Press Release Amgen Wins Patent Case On Enbrel® (etanercept) Court Upholds Validity of Patent Claims Directed …
Nektar Therapeutics Story Everything was going well with Nektar Therapeutics (NKTR) stock during the Conference call …
Nektar Press Release Nektar Therapeutics Results for Q2 of 2019 Nektar Therapeutics (Nasdaq: NKTR) reported its financial …
The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on …
Rhythm Pharmaceuticals From Rhythm Pharmaceuticals (RYTM) we learned that positive, top-line results from two pivotal Phase 3 …
What Have We Learned from the Market's Recent Stock Moves? Well. Did we learn anything from …
In This Column Every day thousands of press releases are issued about biotechnology and pharmaceutical firms. …
Prohost has just finished a very hard task; evaluating its best picks from the biotechnology and …
Nektar Therapeutics We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. …
RegenxBio License Agreement with Pfizer RegenxBio (RGNX) announced a license agreement with Pfizer (PFE). Under the terms of …
Amgen Contrary to our expectations Amgen’s (AMGN) shares declined more than 10% in 2019, instead of rallying. …
Gilead Sciences Activities There is no doubt that Gilead Sciences (GILD) is doing whatever it takes to expand, …
Halozyme and argenx Collaboration argenx (ARGX) dosed the first subject in phase 1 clinical trial for the …
Seattle Genetics Stock Rallied Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and …
CiRA, Takeda & T-CiRA Less than five years ago the Center for iPS Cell Research and Application …
Gilead and Galapagos Global Research Collaboration Gilead Sciences (GILD) and Galapagos NV (GLPG) entered into a 10-year global …
Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib From Exelixis (EXEL) we …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
